2. Search Result
Search Result
Results for "

NAD levels

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

11

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0150
    Nicotinamide
    Maximum Cited Publications
    89 Publications Verification

    Niacinamide; Nicotinic acid amide

    		 Environmental Pollutants Endogenous Metabolite Sirtuin HBV Organoid Cancer
    Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide
  • HY-50876
    Daporinad
    60+ Cited Publications

    FK866; APO866

    		 NAMPT Autophagy Apoptosis mTOR p38 MAPK ERK Cancer
    Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .
    Daporinad
  • HY-123033A
    Nicotinamide riboside chloride
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside Chloride, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside chloride
  • HY-128700
    Nicotinic acid mononucleotide
    1 Publications Verification

    		 Endogenous Metabolite Sirtuin Neurological Disease Inflammation/Immunology Cancer
    Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide
  • HY-128895
    KL1333
    1 Publications Verification

    		 Quinone Reductase Mitochondrial Metabolism Metabolic Disease
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .
    KL1333
  • HY-10079
    CHS-828
    4 Publications Verification

    GMX1778

    		 NAMPT Apoptosis Cancer
    CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
    CHS-828
  • HY-123033
    Nicotinamide riboside

    		Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside
  • HY-W615108B
    β-Nicotinamide mononucleotide, reduced form disodium

    NMNH disodium

    		 Endogenous Metabolite Cancer
    β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD + and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
    β-Nicotinamide mononucleotide, reduced form disodium
  • HY-B0150R
    Nicotinamide (Standard)
    Maximum Cited Publications
    89 Publications Verification

    Niacinamide(Standard); Nicotinic acid amide (Standard)

    		 Reference Standards Endogenous Metabolite Sirtuin Cancer
    Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide (Standard)
  • HY-W614507
    Dihydronicotinamide riboside

    		NADPH Oxidase Apoptosis Bcl-2 Family Metabolic Disease Cancer
    Dihydronicotinamide riboside is a potent NAD + concentration enhancer. Dihydronicotinamide riboside modulates targets BAX, PUMA, NQO2, and IκB kinase. Dihydronicotinamide riboside mediates apoptosis, induces pro-oxidant activity, mitochondrial dysfunction, metabolic dysregulation, redox modulation, and pro-inflammatory M1 phenotype induction. Dihydronicotinamide riboside increases intracellular and mitochondrial NAD + levels, maintains cell survival against NAD +-depleting genotoxins. Dihydronicotinamide riboside can be used for the research of hepatocellular carcinoma .
    Dihydronicotinamide riboside
  • HY-P2909
    Formaldehyde dehydrogenase, Pseudomonas sp
    1 Publications Verification

    		 Biochemical Assay Reagents Others
    Formaldehyde dehydrogenase is a widely occuring enzyme that can catalyze S-hydroxymethylglutathione in the presence of NAD. Formaldehyde dehydrogenase detoxifies formaldehyde within cells through capturing and limiting it from reaching a toxic level. Formaldehyde dehydrogenase can be studied in research on M. tuberculosis .
    Formaldehyde dehydrogenase, Pseudomonas sp
  • HY-157421
    Nampt activator-4

    		NAMPT Metabolic Disease
    Nampt activator-4 is an orally active NAMPT activator, with an EC50 of 58 nM and a Ka of 85.38 nM against human NAMPT. Nampt activator-4 effectively relieves the feedback inhibition of nicotinamide and NAD +, thereby enhancing enzymatic activity and significantly increasing intracellular NAD + levels. Nampt activator-4 exhibits moderate stability in human and mouse liver microsomes. Nampt activator-4 shows low to moderate inhibitory effects on cytochrome P450 (especially CYP3A4). Nampt activator-4 can be used for the research of type 2 diabetes and related metabolic disorders .
    Nampt activator-4
  • HY-131943
    DS44960156

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Neurological Disease Cancer
    DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD +/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers .
    DS44960156
  • HY-123033C
    Nicotinamide riboside malate
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside malate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside malate
  • HY-12628
    GNE-618
    2 Publications Verification

    		 NAMPT Cancer
    GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .
    GNE-618
  • HY-123033AR
    Nicotinamide riboside chloride (Standard)

    		Reference Standards Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside (chloride) (Standard) is the analytical standard of Nicotinamide riboside (chloride). This product is intended for research and analytical applications. Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
    Nicotinamide riboside chloride (Standard)
  • HY-W722277A
    LCC-12 formate

    		Interleukin Related NADH Dehydrogenase TNF Receptor JAK STAT IRAK Inflammation/Immunology
    LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .
    LCC-12 formate
  • HY-173679
    RBN012811

    		PROTACs PARP Interleukin Related STAT Integrin HSV VSV Infection Cancer
    RBN012811 is a highly selective PROTAC-based PARP14 degrader. RBN012811 forms a ternary complex with cereblon by binding to the NAD + site of PARP14, and mediates the specific degradation of PARP14 via the ubiquitin-proteasome pathway (IC50=10 nM). RBN012811 effectively depletes endogenous PARP14 in various cell lines and primary human macrophages, thereby downregulating IL-10 production and IFN-β mRNA levels, increasing phosphorylated STAT1 levels to enhance inflammatory signaling, and inhibiting interferon-induced ADPr condensate formation. RBN012811 also modulates viral replication, exhibiting increased HSV1 replication while reducing VSV replication. RBN012811 has important application value in research related to cancer and viral infections .
    RBN012811
  • HY-123033B
    Nicotinamide riboside tartrate
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside tartrate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside tartrate
  • HY-128700A
    Nicotinic acid mononucleotide triethylamine
    1 Publications Verification

    		 Endogenous Metabolite Sirtuin Metabolic Disease
    Nicotinic acid mononucleotide triethylamine acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide triethylamine exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide triethylamine reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide triethylamine is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide triethylamine
  • HY-125147
    A-1293201

    		NAMPT Cancer
    A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD +/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .
    A-1293201
  • HY-173276
    SARM1-IN-4

    		Toll-like Receptor (TLR) Neurological Disease
    SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the NAD+ hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).
    SARM1-IN-4
  • HY-123033D
    Nicotinamide riboside triflate

    		Endogenous Metabolite Sirtuin Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside triflate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside triflate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside triflate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside triflate
  • HY-B0150A
    Nicotinamide hydrochloride

    Niacinamide hydrochloride; Nicotinic acid amide hydrochloride

    		 Sirtuin Endogenous Metabolite HBV Infection Cancer
    Nicotinamide hydrochloride is a form of vitamin B3 or niacin. Nicotinamide hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide hydrochloride also inhibits SIRT1. Nicotinamide hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide hydrochloride inhibits tumor growth and improves survival. Nicotinamide hydrochloride also has anti-HBV activity .
    Nicotinamide hydrochloride
  • HY-B0399A
    (±)-Carnitine

    DL-Carnitine; DL-Levocarnitine

    		 Mitochondrial Metabolism Metabolic Disease
    (±)-Carnitine (DL-Carnitine) is an orally effective racemic mixture of L-Carnitine (HY-B0399) and D-Carnitine. (±)-Carnitine elevates the mitochondrial NAD +/NADH ratio in the presence of 1,3-butanediol (HY-77490A). (±)-Carnitine does not increase glucose and urea production from L-glutamine, but stimulates propionate gluconeogenesis in rat renal cortical slices, and significantly reduces hepatic ketone body levels in rats fed a diet containing 30% high fat plus 20% 1,3-butanediol .
    (±)-Carnitine
  • HY-119648A
    (E/Z)-CCR-11

    		CD38 Inflammation/Immunology
    (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ .
    (E/Z)-CCR-11
  • HY-W975966
    CPDT

    		Keap1-Nrf2 Neurological Disease
    CPDT is an orally active and highly potent inducer of phase 2 enzymes and an activator of Nrf2. The activities of key phase 2 enzymes, including glutathione S-transferase, NAD(P)H:quinone:oxidoreductase 1 and glutamate cysteine synthetase, and levels of glutathione were elevated by CPDT in rat bladder in vivo and in cultured bladder cells in vitro [2].
    CPDT
  • HY-176237
    Nampt-IN-16

    		NAMPT Apoptosis Cancer
    Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD + and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .
    Nampt-IN-16
  • HY-176284
    OXPHOS-IN-2

    		Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) AMPK Keap1-Nrf2 Cancer
    OXPHOS-IN-2 is an orally active OXPHOS inhibitor. OXPHOS-IN-2 exhibits potent inhibitory activity in PC9 (IC50 = 12.3 nM) and Bxpc-3 cells (IC50 = 250 nM in glucose medium, IC50 = 17.5 nM in galactose medium). OXPHOS-IN-2 decreases the NADH/NAD + ratio and reduces ATP levels. OXPHOS-IN-2 induces tumor cells apoptosis by activating reactive oxygen species (ROS) and downregulating the level of Nrf2. OXPHOS-IN-2 can be used for research on cancer such as non-small cell lung cancer and pancreatic cancer .
    OXPHOS-IN-2
  • HY-B0150S3
    Nicotinamide-d3

    Niacinamide-d3; Nicotinic acid amide-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Organoid Sirtuin HBV Cancer
    Nicotinamide-d3 (Niacinamide-d3) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide-d3
  • HY-178912
    Anti-MRSA agent 39

    		Reactive Oxygen Species (ROS) Bacterial ClpP Infection Inflammation/Immunology
    Anti-MRSA agent 39 is an orally active ClpX modulator that binds Staphylococcus aureus caseinolytic protease X (SaClpX) with high affinity (Kd = 3.6 μM). Anti-MRSA agent 39 exerts antibacterial effects through temperature-dependent inhibition of cell division. Anti-MRSA agent 39 elicits profound metabolic dysregulation in methicillin-resistant Staphylococcus aureus (MRSA), manifesting as significantly reduced ATP levels, elevated reactive oxygen species (ROS), and decreased NAD+/NADH ratio, and accelerates bacterial lysis rates in MRSA ATCC 33591. Anti-MRSA agent 39 significantly increases the proportion of MRSA cells in the mitotic phase, and the cells exhibit obvious morphological abnormalities. Anti-MRSA agent 39 can be used for the study of invasive MRSA infections .
    Anti-MRSA agent 39
  • HY-128895A
    KL1333 hydrochloride

    		Mitochondrial Metabolism Quinone Reductase Metabolic Disease
    KL1333 hydrochloride is an orally active NAD + modulator that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, leading to increased intracellular NAD + levels through NADH oxidation. Elevated NAD + levels trigger activation of SIRT1 and AMPK, and subsequently activate PGC-1α. KL1333 hydrochloride improves energy metabolism and mitochondrial dysfunction in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) fibroblasts. KL1333 hydrochloride protects against cisplatin-induced ototoxicity in mouse cochlear cultures .
    KL1333 hydrochloride
  • HY-155023
    Apoptosis inducer 13

    		Apoptosis Reactive Oxygen Species (ROS) Cancer
    Apoptosis inducer 13 (Compound Ru4) can induce cancer cell apoptosis, and inhibits cancer cell migration and invasion. Apoptosis inducer 13 converts coenzyme NADH to NAD +, and increases intracellular ROS levels .
    Apoptosis inducer 13
  • HY-10079A
    CHS-828 (nicotinate)

    GMX1778 (nicotinate)

    		 NAMPT Apoptosis Cancer
    CHS-828 nicotinate is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 nicotinate (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
    CHS-828 (nicotinate)
  • HY-117420
    CM764

    		Sigma Receptor Cancer
    CM764 is an activator for sigma receptor with Ki of 86.6 and 3.5 nM for sigma-1 receptor and sigma-2 receptor. CM764 increases cytoplasmic calcium, NAD +/NADH, and ATP levels, and decreases the concentration of ROS .
    CM764
  • HY-10079R
    CHS-828 (Standard)

    GMX1778 (Standard)

    		 Reference Standards NAMPT Apoptosis Cancer
    CHS-828 (Standard) is the analytical standard of CHS-828. This product is intended for research and analytical applications. CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity .
    CHS-828 (Standard)
  • HY-119159
    AS1604498

    		NAMPT Caspase Apoptosis Cancer
    AS1604498 is a highly specific competitive inhibitor of human NAMPT, with an IC50 of 44.4 nM. AS1604498 functionally inhibits NAMPT enzymatic activity, reduces nicotinamide mononucleotide production, decreases intracellular NAD levels, activates caspase 3/7 and induces cancer cell apoptosis. AS1604498 is applicable to research related to chronic myeloid leukemia .
    AS1604498
  • HY-182025
    NAD+ potentiator-1

    		Endogenous Metabolite Neurological Disease
    NAD+ potentiator-1 (Compound R-4b) is a NAD potentiator. NAD+ potentiator-1 increases NAD levels in primary cortical neurons. NAD+ potentiator-1 is used for the research of neurodegenerative diseases .
    NAD+ potentiator-1
  • HY-186178
    CD38-IN-6

    		CD38 Metabolic Disease Inflammation/Immunology
    CD38-IN-6 is an orally active CD38 inhibitor. CD38-IN-6 regulates NAD + metabolite levels in the liver of aged obese mice by increasing NAD + and NMN levels, and decreasing NAM and ADPR levels. CD38-IN-6 alleviates inflammatory responses in mice. CD38-IN-6 can be used for research related to obesity and inflammation .
    CD38-IN-6
  • HY-184246
    SR-34831

    		NAMPT Neurological Disease
    SR-34831 is a NAMPT activator, NAD level stabilizer and neuroprotective agent. SR-34831 enhances the enzymatic activity of human NAMPT, prevents intracellular NAD depletion, and counteracts neuronal death induced by toxic misfolded prion proteins. SR-34831 exhibits metabolic stability in human liver microsomes and can be used for the research of protein misfolding neurodegenerative diseases .
    SR-34831
  • HY-B0150G
    Nicotinamide

    Niacinamide; Nicotinic acid amide

    		 Endogenous Metabolite Sirtuin HBV Infection Cancer
    Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide
  • HY-W744757
    Nicotinamide-15N

    Niacinamide-15N; Nicotinic acid amide-15N

    		 Isotope-Labeled Compounds Others
    Nicotinamide- 15N (Niacinamide- 15N) is the deuterium labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.
    Nicotinamide-15N
  • HY-B0150S4
    Nicotinamide-13C,15N

    Niacinamide-13C,15N; Nicotinic acid amide-13C,15N

    		 Isotope-Labeled Compounds Sirtuin Environmental Pollutants HBV Organoid Endogenous Metabolite Cancer
    Nicotinamide- 13C, 15N (Niacinamide- 13C, 15N) is the 13C- and 15N-labeled Nicotinamide (HY-B0150). Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide-13C,15N
  • HY-50876A
    Daporinad hydrochloride

    FK866 hydrochloride; APO866 hydrochloride

    		 NAMPT Autophagy Apoptosis mTOR p38 MAPK ERK Inflammation/Immunology Cancer
    Daporinad (FK866) hydrochloride is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad hydrochloride depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad hydrochloride causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad hydrochloride induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad hydrochloride can be used for the study of myeloma, liver cancer, and immunosuppression .
    Daporinad hydrochloride
  • HY-182062
    NAMPT activator-9

    		NAMPT E1/E2/E3 Enzyme Neurological Disease
    NAMPT activator-9 (Compound DIPM) is an allosteric, non-competitive NAMPT activator, with an EC50 of 3.366 μM against hNAMPT. NAMPT activator-9 enhances the enzymatic activity of NAMPT via an allosteric, non-competitive mechanism. NAMPT activator-9 increases intracellular NAD + levels. NAMPT activator-9 restores myotube diameter and reduces the expression of atrophy markers Atrogin-1 and MuRF1. NAMPT activator-9 is applicable to research related to muscle atrophy .
    NAMPT activator-9
  • HY-W008927
    Fluoxastrobin

    		Fungal Reactive Oxygen Species (ROS) DNA/RNA Synthesis Apoptosis Infection
    Fluoxastrobin is a fungicide. By binding to NAD-dependent epimerase/dehydratase, Fluoxastrobin interferes with electron transport, reduces ATP production and inhibits mycelial growth, thereby effectively controlling foliar diseases of tea plants. Fluoxastrobin induces oxidative stress by increasing ROS levels and lipid peroxidation, causes DNA damage and promotes apoptosis; meanwhile, it shows high acute toxicity to Danio rerio embryos and larvae. Fluoxastrobin can be used in research related to tea foliar diseases (including tea red leaf spot and tea gray leaf spot) .
    Fluoxastrobin
  • HY-W615108BR
    β-Nicotinamide mononucleotide, reduced form disodium (Standard)

    		Endogenous Metabolite Reference Standards Cancer
    β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B). This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
    β-Nicotinamide mononucleotide, reduced form disodium (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: